Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Pfaar

Showing results (31-40 of 306) with videos related to

Pageof 31
Sort By:
Allergologie Select|March 17, 2023
Clinical endpoints in allergen immunotherapy: State of the art 2022Roy Gerth van Wijk, Ludger Klimek, Oliver Pfaar
American Journal of Rhinology & Allergy|February 20, 2010
Safety of a depigmented, polymerized vaccine for the treatment of allergic rhinoconjunctivitis and allergic asthmaOliver Pfaar, Ludger Klimek, Angelika Sager, et al.
The Journal of Allergy and Clinical Immunology. in Practice|July 8, 2023
Is "Maintenance" a Misnomer? A Narrative Framework Setting the Right Expectations of Allergen ImmunotherapyKymble Spriggs, Oliver Pfaar, Ruby Pawankar, et al.
Current Allergy and Asthma Reports|April 1, 2014
Aspirin desensitization: useful treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in aspirin-exacerbated respiratory disease (AERD)?Ludger Klimek, Ralph Dollner, Oliver Pfaar, et al.
Current Opinion in Allergy and Clinical Immunology|April 23, 2015
Clinically relevant outcome measures for new pharmacotherapy, allergen avoidance and immunotherapy trials in allergic rhinoconjunctivitisOliver Pfaar, Ludger Klimek, Roy Gerth van Wijk
Clinical and Translational Allergy|November 25, 2023
A high-dose, depigmented polymerized birch pollen extract for subcutaneous allergen immunotherapy has a favourable efficacy/safety ratioOliver Pfaar, Angelika Sager, Ralph Mösges, et al.
Current Opinion in Allergy and Clinical Immunology|April 23, 2010
Cluster protocols in SCIT: enough evidence for practical use?Oliver Pfaar, Sarah Leitzbach, Karl Hörmann, et al.
Allergy|June 27, 2020
COVID-19: A series of important recent clinical and laboratory reports in immunology and pathogenesis of SARS-CoV-2 infection and care of allergy patientsOliver Pfaar, Maria J Torres, Cezmi A Akdis
Allergologie Select|December 16, 2022
Digital health for allergen immunotherapyStephanie Dramburg, Paolo Maria Matricardi, Oliver Pfaar, et al.
Current Allergy and Asthma Reports|June 7, 2013
Recombinant allergen immunotherapy: clinical evidence of efficacy--a reviewMelina Makatsori, Oliver Pfaar, Ramon Lleonart, et al.
Pageof 31

Showing results (31-40 of 306) with videos related to

Sort By:
Pageof 31
Allergologie Select|March 17, 2023
Clinical endpoints in allergen immunotherapy: State of the art 2022Roy Gerth van Wijk, Ludger Klimek, Oliver Pfaar
American Journal of Rhinology & Allergy|February 20, 2010
Safety of a depigmented, polymerized vaccine for the treatment of allergic rhinoconjunctivitis and allergic asthmaOliver Pfaar, Ludger Klimek, Angelika Sager, et al.
The Journal of Allergy and Clinical Immunology. in Practice|July 8, 2023
Is "Maintenance" a Misnomer? A Narrative Framework Setting the Right Expectations of Allergen ImmunotherapyKymble Spriggs, Oliver Pfaar, Ruby Pawankar, et al.
Current Allergy and Asthma Reports|April 1, 2014
Aspirin desensitization: useful treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in aspirin-exacerbated respiratory disease (AERD)?Ludger Klimek, Ralph Dollner, Oliver Pfaar, et al.
Current Opinion in Allergy and Clinical Immunology|April 23, 2015
Clinically relevant outcome measures for new pharmacotherapy, allergen avoidance and immunotherapy trials in allergic rhinoconjunctivitisOliver Pfaar, Ludger Klimek, Roy Gerth van Wijk
Clinical and Translational Allergy|November 25, 2023
A high-dose, depigmented polymerized birch pollen extract for subcutaneous allergen immunotherapy has a favourable efficacy/safety ratioOliver Pfaar, Angelika Sager, Ralph Mösges, et al.
Current Opinion in Allergy and Clinical Immunology|April 23, 2010
Cluster protocols in SCIT: enough evidence for practical use?Oliver Pfaar, Sarah Leitzbach, Karl Hörmann, et al.
Allergy|June 27, 2020
COVID-19: A series of important recent clinical and laboratory reports in immunology and pathogenesis of SARS-CoV-2 infection and care of allergy patientsOliver Pfaar, Maria J Torres, Cezmi A Akdis
Allergologie Select|December 16, 2022
Digital health for allergen immunotherapyStephanie Dramburg, Paolo Maria Matricardi, Oliver Pfaar, et al.
Current Allergy and Asthma Reports|June 7, 2013
Recombinant allergen immunotherapy: clinical evidence of efficacy--a reviewMelina Makatsori, Oliver Pfaar, Ramon Lleonart, et al.
Pageof 31